Navigation Links
Vectibix(R) in Combination With Chemotherapy Significantly Improves Progression-Free Survival in Second-Line Metastatic Colorectal Cancer
Date:9/22/2009

THOUSAND OAKS, Calif., Sept. 22 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced detailed results from the Phase 3 '181' trial evaluating Vectibix((R)) (panitumumab) in combination with FOLFIRI (an irinotecan based chemotherapy), as a second-line treatment for metastatic colorectal cancer (mCRC). In this trial, Vectibix significantly improved progression-free survival (PFS) in patients with KRAS wild-type mCRC. These results were presented at the 2009 ECCO 15 - ESMO 34 European Multidisciplinary Congress in Berlin, Germany (Abstract Number 14LBA).

The addition of Vectibix to FOLFIRI significantly improved median PFS (co-primary endpoint) by two months (5.9 versus 3.9 months for patients treated with FOLFIRI alone, hazard ratio 0.73, p=0.004) in patients with KRAS wild-type mCRC. Although numerically greater (14.5 months versus 12.5 months; hazard ratio 0.85), the improvement in median overall survival (co-primary endpoint) in the Vectibix arm did not achieve statistical significance (p=0.115) in the same patient population.

Further, the addition of Vectibix to FOLFIRI resulted in greater than a three-fold improvement (35 percent versus 10 percent) in response rate in the KRAS wild-type patient population as measured by a blinded central review.

"This study showed that Vectibix can be safely administered in combination with FOLFIRI chemotherapy. Vectibix delayed disease progression by more than half compared to FOLFIRI alone in patients with previously treated KRAS wild-type colorectal cancer," said Marc Peeters, M.D., Ph.D., coordinator of Digestive Oncology Unit, University Hospital Ghent and the study's principal investigator. "Further, the response rate seen in this trial is among the highest ever re
'/>"/>

SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Vectibix(R) in Combination With Chemotherapy Significantly Improved Progression-Free Survival in First-Line Metastatic Colorectal Cancer
2. Vectibix(R) Significantly Improved Progression-Free Survival in Second-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer
3. CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia
4. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
5. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
6. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
7. Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
8. Vion Pharmaceuticals Announces Initiation of a Phase I/II Trial of Cloretazine(R) (VNP40101M) in Combination with Temodar(R) in Adult Brain Tumors
9. New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy
10. New Data Show Ceftobiprole as Effective as Combination Therapy in Treating Patients With Complicated Skin Infections, Including MRSA
11. European Unions CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... , July 22, 2014 Sanofi Pasteur, the ... SNY ), announced today that the first lots of Fluzone ... season have been released by the U.S. Food and Drug ... 21, 2014, representing the first of at least 65 million ... will be delivered to U.S. health care providers and pharmacies ...
(Date:7/22/2014)...  Halozyme Therapeutics, Inc. (NASDAQ: HALO ) ... of patients in its ongoing Phase 2 trial (Study ... the revised clinical protocol agreed to with the FDA ... Halozyme,s proprietary recombinant human hyaluronidase under development for the ... "Our diligent effort to rapidly re-initiate patient enrollment ...
(Date:7/22/2014)...  July 22, 2014 The ... Reuters , the world,s leading provider of ... announced Cortellis Clinical Trials Intelligence , ... industry-first milestone with the documentation of more ... professionals with greater and quicker access to ...
Breaking Medicine Technology:Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 2Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 3Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 4Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 5Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 6Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 7Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer 2Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer 3Thomson Reuters Cortellis Clinical Trials Intelligence Reaches Industry Milestone with 180,000 Clinical Trials 2Thomson Reuters Cortellis Clinical Trials Intelligence Reaches Industry Milestone with 180,000 Clinical Trials 3
... Cardiac Science Corporation , a global leader in automated ... monitoring devices that connect to electronic medical record ... it has completed certification with Allscripts Professional ... connectivity solution for its resting ECG, stress, and Holter ...
... and Drug Commissioner Dr. Margaret Hamburg today conducted an unusual ... a forum hosted by the National Organization for Rare Disorders ... Hamburg could share with the patient advocates her vision for ... concerns. "I come today to ask for your ...
Cached Medicine Technology:Cardiac Science Extends Device Connectivity to Allscripts Professional™ Electronic Health Record 2Cardiac Science Extends Device Connectivity to Allscripts Professional™ Electronic Health Record 3Cardiac Science Extends Device Connectivity to Allscripts Professional™ Electronic Health Record 4Cardiac Science Extends Device Connectivity to Allscripts Professional™ Electronic Health Record 5NORD Hosts Forum for FDA Commissioner and Patient Leaders 2
(Date:7/22/2014)... (PRWEB) July 22, 2014 Dr. Jeremy ... his surgical colleagues, have recently discussed the reasons for ... leaders in the periodontics profession are seeing the amount ... up exponentially. In fact, one surgeon reported that over ... implants. Although dental implants have a very high success ...
(Date:7/22/2014)... Baltimore, MD (PRWEB) July 22, 2014 Aaron ... President at The Hearing and Speech Agency for ... in 2011. Of his appointment, Marshall states, "“Serving on ... about how others are living and helps me remember how ... University School of Law graduate, Aaron also has a B.S. ...
(Date:7/22/2014)... Steven Reinberg HealthDay Reporter ... are obese during pregnancy may be more likely to have ... "We found that, compared with children born from mothers ... during pregnancy had up to 20 to 30 percent higher ... assistant professor of pediatrics at Children,s Hospital of Pittsburgh. ...
(Date:7/22/2014)... hysterectomy using electric power morcellation, uterine cancers were present ... the procedure, according to a study published by ... in which the uterus is fragmented into smaller pieces, ... Despite the commercial availability of electric power morcellators for ... at the time of electric power morcellation (in this ...
(Date:7/22/2014)... Ross Feldman says women are often in the dark. Historically, ... however, data has shown that post-menopausal women are just as ... likely to be adequately diagnosed and treated. New research from ... Journal of Clinical Pharmacology brings to light a genetic ... which women are more prone to heart disease. , The ...
Breaking Medicine News(10 mins):Health News:Dr. Jeremy Ueno Can Help Treat Patients That Have Failing Implants 2Health News:Dr. Jeremy Ueno Can Help Treat Patients That Have Failing Implants 3Health News:New Board President for Baltimore-based Nonprofit 2Health News:Obesity During Pregnancy Linked to Raised Asthma Risk in Kids 2Health News:Obesity During Pregnancy Linked to Raised Asthma Risk in Kids 3Health News:Study examines presence of uterine cancers at the time of hysterectomy using morcellation 2Health News:Gene variant identified as a heart disease risk factor for women 2
... Revenues increase 166% versus Q1 2007 ... Six new Centers opened to date in 2008, VANCOUVER, May ... revenues of $1.35 million for,the three months ended March 31, 2008 ... an increase of 166%. The Company,s net,loss decreased to $0.96 million ...
... Israel, May 29 Elbit Imaging Ltd.,(Nasdaq: EMITF ... for the,first quarter of 2008., Loss for the ... US$ 1.0 million) of which loss of NIS 27.3 ... holders of,the Company, while profit of NIS 23.8 million ...
... from the Oregon Health & Science University Cancer Institute ... hope to many patients. , Researchers have discovered that ... can occur in a gene called the KIT gene. ... and mucosal melanomas, which are less common, but highly ...
... bacteria break their metabolic processes into chunks. That may ... have now figured out the factors that tend to ... Santa Fe Institute and Stanford University, together with Anat ... University, constructed the metabolic networks of many species of ...
... Society for Therapeutic Radiology has selected the recipients of ... bestows. Christopher Rose, M.D., FASTRO, and Joel Tepper, M.D., ... 50th Annual Meeting in Boston during the Gold Medal ... "It seems particularly fitting that we recognize these two ...
... risk of dying within month, study finds , , THURSDAY, May ... more likely to die within 30 days than stroke patients ... Seizures may be a sign of significant brain injury and ... This study found that the overall incidence of seizures within ...
Cached Medicine News:Health News:CRH Medical reports Q1 2008 results 2Health News:CRH Medical reports Q1 2008 results 3Health News:CRH Medical reports Q1 2008 results 4Health News:Elbit Imaging Ltd. Announces First Quarter Results for 2008 2Health News:Elbit Imaging Ltd. Announces First Quarter Results for 2008 3Health News:Elbit Imaging Ltd. Announces First Quarter Results for 2008 4Health News:Elbit Imaging Ltd. Announces First Quarter Results for 2008 5Health News:Elbit Imaging Ltd. Announces First Quarter Results for 2008 6Health News:Elbit Imaging Ltd. Announces First Quarter Results for 2008 7Health News:Elbit Imaging Ltd. Announces First Quarter Results for 2008 8Health News:Elbit Imaging Ltd. Announces First Quarter Results for 2008 9Health News:Elbit Imaging Ltd. Announces First Quarter Results for 2008 10Health News:Elbit Imaging Ltd. Announces First Quarter Results for 2008 11Health News:Elbit Imaging Ltd. Announces First Quarter Results for 2008 12Health News:Elbit Imaging Ltd. Announces First Quarter Results for 2008 13Health News:OHSU Cancer Instutute researchers find abnormalities in gene for melanoma 2Health News:ASTRO announces 2008 gold medalists 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: